pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Health policy crackdown warnings span from China to New York, says STAT newsletter

Oct 22, 2026·read at STAT ↗Neutral

STAT's D.C. Diagnosis newsletter highlights growing concerns about health policy crackdowns that could affect regions from China to New York.

In a recent Ohio appearance, the vice president used a Titanic metaphor to describe the economy, saying change cannot happen overnight.

A KFF survey cited in the piece shows the average premium increase for an employer‑sponsored family health plan is 9% this year, with even higher rises for workers at smaller companies.

The full analysis is available to STAT+ subscribers, with pricing tiers ranging from monthly to annual plans.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Crackdowns loom, from China to New York”

read at STAT ↗
440 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
drugs
Rare Disease
topics
ApprovalRare Disease

related stories

  • Jun 29Theravance, after clinical setbacks, agrees to $929M buyoutBioPharma Dive
  • Jun 18Moderna flu vaccine wins unanimous support from FDA panelBioPharma Dive
  • Jun 17UniQure to file gene therapy for approval, reflecting major shifts at FDABioPharma Dive
  • Jun 9Grace Science says FDA bottleneck jeopardizes rare disease therapyEndpoints
  • Jun 4STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and moreSTAT